Ovarian Cancer gets Orphan Drugs as ZW25 and ZW33; approves FDA
Zymeworks, a pharmaceutical company, announces that Food and Drug Association (FDA) has granted orphan drug designation .
Release Date: 17-Oct-2016
Zymeworks, a pharmaceutical company, announces that Food and Drug Association (FDA) has granted orphan drug designation to ZW25 and ZW33 for effective treatment of ovarian cancer.
ZW25 is a novel bispecific antibody designed to target two different epitopes of the HER-2 protein, overexpressed on the surface of several tumor types, including ovarian, lung, breast and gastric cancers. ZW33 is a drug-conjugated version of ZW25.The Company is looking for better possible treatment followed best results in patients suffering from ovarian cancer.
For Orphan Drug Clinical Insight Reports Contact: email@example.com
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.